Opendata, web and dolomites

ANDROTEST

Point of care test for non invasive differential diagnosis of obstrutive and non-obstructive azoospermia in male fertility

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "ANDROTEST" data sheet

The following table provides information about the project.

Coordinator
TORO VENTURES FINANCIAL AND MANAGEMENT SERVICES SL 

Organization address
address: CALLE MIGUEL VILLANUEVA 2 6 PISO PUERTA 3
city: LOGRONO
postcode: 26001
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TORO VENTURES FINANCIAL AND MANAGEMENT SERVICES SL ES (LOGRONO) coordinator 50˙000.00

Map

 Project objective

The project ANDROTEST aims at the development of a non-invasive point-of-care device for the differential diagnosis of obstructive and non-obstructive azoospermia (medical condition of a man not having any measurable level of sperm in his semen) in male infertility cases. Human infertility affects about 25% of couples. For many years, it was thought that infertility was a “woman thing”. Nowadays it is well known that infertility is not such a woman thing, being estimated that in 40-50% of infertility cases, the issue is on the man’s side. One of the most severe forms of male infertility is azoospermia, which is characterized by an absence of sperm in the semen. Azoospermia is diagnosed in 20% of subfertile men and has two forms: obstructive azoospermia (OA) and non-obstructive azoospermia (NOA). OA is caused by a physical obstruction in the male reproductive tract. NOA is a more complicated infertility syndrome with the azoospermia being secondary to a failure to produce sperm. For most men with azoospermia, testicular biopsy is currently the only method to definitively distinguish between OA and NOA. Testicular biopsy is a surgical intervention procedure to remove a small sample of tissue from one or both testicles for further examination under a microscope. The procedure has to be performed by a surgeon or an urologist in an operating room and under local anaesthesia. It is therefore, an invasive procedure that implies significant costs for the healthcare systems and that needs more than 2 weeks to deliver the results, because of the need for expert evaluation of the sampled tissue. The invasiveness of the procedure, the elevated costs and the long times needed to deliver the results, sustain the urgent need for an alternative non-invasive and faster approach with better diagnostic potential at lower costs. This need is the one we have identified as a huge business opportunity we seek embracing.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ANDROTEST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ANDROTEST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More